Brind.

BBOT is conducting preclinical studies on several drug candidates, including BBO-10203, BBO-8520, and BBO-11818, targeting pathways like KRAS and PI3Kα.

Steady: 0 in the last 7 days Updated sep 12

The latest in this situation

  1. BBO-8520, a drug candidate from BridgeBio Oncology Therapeutics, demonstrated a high response rate when combined with pembrolizumab. The compound functions as a KRASG12C inhibitor.

How it started

1 report, 1 independent, last reported Aug 1. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

BBOT is conducting preclinical studies on several drug candidates, including BBO-10203, BBO-8520, and BBO-11818, targeting pathways like KRAS and PI3Kα.

How it developed

Newest first. Tap a step to see who reported it.
  1. BBO-8520, a drug candidate from BridgeBio Oncology Therapeutics, demonstrated a high response rate when combined with pembrolizumab. The compound functions as a KRASG12C inhibitor.Sub-event
  2. BBOT is advancing multiple drug candidates (BBO-10203, BBO-8520, BBO-11818) in studies against targets like KRAS and PI3Kα.1 source

Coverage

Newest first; wire copies grouped